{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:12:39Z","timestamp":1783440759964,"version":"3.54.6"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jdin.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:30:29Z","timestamp":1737678629000},"page":"45-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pemphigus risk following programmed death receptor-1, programmed death ligand-1, or cytotoxic T-lymphocyte-associated protein 4 inhibitors: A 1:1 propensity-matched, global, retrospective cohort study"],"prefix":"10.1016","volume":"19","author":[{"given":"Justin","family":"Baroukhian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Seiffert-Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh A.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jdin.2025.01.004_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jdin.2025.01.004_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.691980","article-title":"Case report: autoimmune pemphigus vulgaris in a patient treated with cemiplimab for multiple locally advanced cutaneous squamous cell carcinoma","volume":"11","author":"Buquicchio","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jdin.2025.01.004_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1259071","article-title":"Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review","volume":"14","author":"Nakamura","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jdin.2025.01.004_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00262","article-title":"Recurrence of pemphigus vulgaris under nivolumab therapy","volume":"6","author":"Krammer","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.jdin.2025.01.004_bib5","article-title":"HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment","volume":"10","author":"Gandarillas","year":"2023","journal-title":"Front Med"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725000094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725000094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T17:57:20Z","timestamp":1744999040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328725000094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":5,"alternative-id":["S2666328725000094"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2025.01.004","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pemphigus risk following programmed death receptor-1, programmed death ligand-1, or cytotoxic T-lymphocyte-associated protein 4 inhibitors: A 1:1 propensity-matched, global, retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}